Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Long-Term Deferred Tax (2021)

Stoke Therapeutics has reported Long-Term Deferred Tax over the past 1 years, most recently at $66.0 million for Q4 2021.

  • For Q4 2021, Long-Term Deferred Tax changed N/A year-over-year to $66.0 million; the TTM value through Dec 2021 reached $66.0 million, changed N/A, while the annual FY2021 figure was $66.0 million, N/A changed from the prior year.
  • Long-Term Deferred Tax for Q4 2021 was $66.0 million at Stoke Therapeutics.
  • Over five years, Long-Term Deferred Tax peaked at $66.0 million in Q4 2021 and troughed at $66.0 million in Q4 2021.